MERCK CO. DL-,01/ US58933Y1055 /
25/07/2024 08:01:07 | Chg. +2.00 | Volume | Bid18:31:40 | Ask18:31:40 | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
116.20EUR | +1.75% | 0 Turnover: 0.00 |
116.60Bid Size: 1,000 | 117.00Ask Size: 1,000 | 297.83 bill.EUR | - | - |
GlobeNewswire
25/06
Qure.ai announces strategic investment by Merck Global Health Innovation Fund to boost innovation of...
GlobeNewswire
18/06
Arch Biopartners Announces University of Calgary Ethics Approval to Proceed with Phase II Trial for ...
GlobeNewswire
06/06
Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepin...
GlobeNewswire
03/06
Biolojic Design Enters into a Multi-Target Drug Discovery Collaboration with Merck KGaA, Darmstadt, ...
GlobeNewswire
29/05
Jeito Capital announces the acquisition by Merck & Co (NYSE: MRK) of its portfolio company EyeBio fo...
GlobeNewswire
07/05
CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination wi...
GlobeNewswire
06/05
Press Release Biocartis NV: Biocartis and Merck to Collaborate on Improving Patient Access to Person...
GlobeNewswire
06/03
IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Can...
GlobeNewswire
04/03
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Ger...
GlobeNewswire
21/12/2023
Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac ...
GlobeNewswire
19/12/2023
Unnatural Products, Inc. Announces $32 Million in Series A Funding Led by Merck Global Health Innova...